Abbes Houwaida, Soria-Chacartegui Paula, Omezzine Asma, Abad-Santos Francisco, Zubiaur Pablo
Clinical Pharmacology Department, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria La Princesa (IP), Universidad Autónoma de Madrid (UAM), 28049 Madrid, Spain.
Biochemistry Department, LR12SP11, Sahloul University Hospital, Sousse 4054, Tunisia.
Pharmaceuticals (Basel). 2025 Mar 28;18(4):493. doi: 10.3390/ph18040493.
A systematic review was conducted to compile all the evidence on the impact of and genetic variants on the response to β-blockers, used for the management of cardiovascular diseases. After searching in PubMed, PharmGKB, and the Cochrane Central Register of Controlled Trials including terms related to these drugs, genes, and pathologies, 1182 articles were retrieved, 29 of which met the inclusion criteria. A β-adrenoreceptor (ADRB) blockade qualitative variable was inferred for all the associations between genetic variants and clinical phenotypes. The relationship between rs1801253 (G>C) C allele and higher receptor blockade showed a moderate overall level of evidence, reaching a high level on its relationship with higher reduction in the systolic (SBP) and diastolic blood pressure and heart rate (HR). The relationship between rs1801252 (A>G) G allele and lower receptor blockade reached an overall high level of evidence, considering its impact on the reduction in the SBP, HR, left ventricular end-diastolic diameter, and incidence of major cardiovascular events. The relationship between rs1042714 (G>C) C allele and lower receptor blockade reached a moderate overall level of evidence due to its impact on HR, pulmonary wedge pressure, and left ventricular ejection fraction response. The rs1042713 (G>A) A allele was associated with higher receptor blockade and higher HR reduction with a low level of evidence. The genotyping of both variants may be clinically useful; further investigation is required on the relevance of both variants. Further research is warranted to determine the clinical usefulness of preemptive genotyping.
进行了一项系统综述，以汇总关于[具体基因1]和[具体基因2]基因变异对用于心血管疾病管理的β受体阻滞剂反应影响的所有证据。在PubMed、PharmGKB和Cochrane对照试验中央注册库中进行检索，纳入与这些药物、基因和病理相关的术语后，共检索到1182篇文章，其中29篇符合纳入标准。推断了基因变异与临床表型之间所有关联的β肾上腺素能受体（ADRB）阻滞定性变量。[具体基因1] rs1801253（G>C）C等位基因与更高的受体阻滞之间的关系总体证据水平中等，在其与收缩压（SBP）、舒张压和心率（HR）更大幅度降低的关系方面达到高水平。[具体基因1] rs1801252（A>G）G等位基因与更低的受体阻滞之间的关系总体证据水平高，考虑到其对SBP、HR、左心室舒张末期直径和主要心血管事件发生率降低的影响。[具体基因1] rs1042714（G>C）C等位基因与更低的受体阻滞之间的关系总体证据水平中等，因为其对HR、肺楔压和左心室射血分数反应有影响。[具体基因1] rs1042713（G>A）A等位基因与更高的受体阻滞和更高的HR降低相关，证据水平低。这两种[具体基因1]变异的基因分型可能具有临床应用价值；需要进一步研究这两种[具体基因1]变异的相关性。有必要进行进一步研究以确定[具体基因1]预分型的临床应用价值。
